REG - Cambridge Cognition - Issue of Equity and Total Voting Rights

Cambridge Cognition HoldingsAnnouncement

26/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240726:nRSZ9167Xa&default-theme=true

RNS Number : 9167X  Cambridge Cognition Holdings PLC  26 July 2024

26 July 2024

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, announces that further to the
announcement on 12 October 2022 regarding the acquisition of eClinicalHealth
Limited ("Clinpal"), the Company has today issued 229,984 new ordinary shares
of £0.01 each in the share capital of the Company ("New Ordinary Shares") at
an issue price of 132.97 pence per New Ordinary Share to certain shareholders
of Clinpal, representing approximately £0.3m of the contingent
consideration.  No further consideration is due to former shareholders of
Clinpal.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM ("Admission") and it is expected that
such Admission will take place on or around 8:00 a.m. on or around 31 July
2024.

 

In accordance with the provision of the Disclosure Guidance and Transparency
Rules of the Financial Conduct Authority, the Company confirms that, following
the issue of the New Ordinary Shares, its issued ordinary share capital will
comprise 41,940,413 Ordinary Shares. There are no shares held in treasury
therefore the total number of voting rights in the Company is 41,940,413. This
figure may be used by shareholders as the denominator for the calculation by
which they will determine if they are required to notify their interest in, or
a change to their interest in Cambridge Cognition under the FCA's Disclosure
and Transparency Rules.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                     Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer               press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Emma Earl / Freddy Crossley / Mark Rogers            (Corporate Finance)

 Rupert Dearden                                       (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)               Tel: 020 3903 7715

 David Poutney / Nicholas Chambers

 Hudson Sandler (Financial PR and IR)                 Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                       cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit: https://cambridgecognition.com/
(https://cambridgecognition.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEPPUUCMUPCGQA